Assessing Pharmacokinetics and Safety of Therapeutic Alpha-1-Microglobulin in First-in-Human Kidney Transplantation: A Noncomparative Open-Label Multiple-Dose Phase 1b Study

Assessing Pharmacokinetics and Safety of Therapeutic Alpha-1-Microglobulin in First-in-Human Kidney Transplantation: A Noncomparative Open-Label Multiple-Dose Phase 1b Study

Background. RMC-035 is a modified version of alpha-1-microglobulin, an endogenous protein developed as a renoprotective agent. Its intended use is to reduce the risk of irreversible loss of kidney function in cardiac surgery patients and to reduce delayed graft function in kidney transplant recipien...

Full description

Saved in:
Bibliographic Details
Main Authors: Johan E. A. Nordström, MD, Lars M. Wennberg, PhD, MD, Greg Nowak, PhD, MD, Tobias E. Larsson, PhD, MD, Sara J. Thuresson, MSc, Michael Reusch, MD
Format: Article
Language:English
Published: Wolters Kluwer 2024-12-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001727
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items